雄激素受体对三阴性乳腺癌患者生存状况影响的Meta分析

doi:10.13481/j.1671-587x.20170115

Abstract

Abstract:

Objective: To evaluate the influence of androgen receptor(AR) in the living conditions in the triple-negative breast cancer patients,and to explore whether there is a difference in the survival rates between the breast cancer patients with positive AR and those with negative AR.Methods: PubMed,Medline,EMbase,Cochrane Library,CNKI,CBM,Wanfang,and VIP databases were systemically searched to collect the published studies about the influence of AR in the living conditions of the patients with triple-negative breast cancer. Meta-analysis was performed by RevMan 5.1 software.Results: There were 9 cohort studies were selected for Meta-analysis,4 Chinese and 5 English.1 295 patients included 362 AR+ and 933 AR-.In evaluation of study quality,7 studies scored more than 7,and 2 studies less than 6.The overall survival(OS) and disease-free survival (DFS) of the triple-negative breast cancer patients with AR+ and AR- had no differences (OR=0.70,95%CI:0.33-1.46,P=0.32;OR=0.41,95%CI:0.17-0.98,P=0.05). The 5-year DFS and OS of the AR+ patients were higher than the AR-patients(OR=0.30,95%CI:0.11-0.86,P=0.02;OR=0.19,95%CI:0.11-0.33,P<0.01).Conclusion: AR has a positive impact on the 5-year DFS and OS of the triple-negative breast cancer patients,but its influence in the 3-year and 10-year survival can't be confirmed.

Key words: triple-negative breast cancer, estrogen receptor, Meta-analysis, disease-free survival, overall survival

CLC Number:

R737.9

ZHANG Chengshuai, PAN Cuiliu, GAO Yanan, HAN Bing, ZHANG Zhiru, LI Feng. Meta-analysis on influence of androgen receptor in living conditions of patients with triple-negative breast cancer[J].Journal of Jilin University Medicine Edition, 2017, 43(01): 73-79.

References

[1] 刘晓丽,姜达,崔彦芝.三阴性乳腺癌雄激素受体研究进展[J].中国癌症杂志,2016,26(5):466-470.
[2] 彭燕.三阴性乳腺癌潜在的肿瘤预后生物标志[J].北京大学学报:医学版,2012,44(5):666-672.
[3] 智英辉,尼杰,田秀芳,等.雄激素受体在三阴性乳腺癌的表达及其预后意义[J].重庆医学,2012,41(27):2812-2815.
[4] 田慧玲,周凤华,郑洁,等.Ki-67、AR及FRA在三阴性乳腺癌中的表达及意义[J].现代肿瘤医学,2014,22(4):830-833.
[5] 李永,田沛琦,崔树德,等.不同AR状态三阴性乳腺癌新辅助化疗疗效分析[J].河南医学研究,2015,24(7):45-46.
[6] 马蓉,姚宇锋,龚建平,等.雄激素受体在三阴性乳腺癌中的表达及其预后价值[J].肿瘤预防与治疗,2013,26(3):122-124.
[7] Tang D,Xu S,Zhang Q,et al.The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer[J].Med Oncol,2012,29(2):526-533.
[8] Luo X,Shi YX,Li ZM,et al.Expression and clinical significance of androgen receptor in triple negative breast cancer[J].Chin J Cancer,2010,29(6):585-590.
[9] Mrklic I, Pogorelic Z,Capkun V,et al.Expression of androgen receptors in triple negative breast carcinomas[J].Acta Histochem,2013,115(4):344-348.
[10] Gonzalez-Angulo AM,Stemke-Hale K,Palla SL,et al.Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer[J].Clin Cancer Res,2009,15(7):2472-2478.
[11] He J,Peng R,Yuan Z,et al.Prognostic value of androgen receptor expression in operable triple-negative breast cancer:a retrospective analysis based on a tissue microarray[J].Med Oncol,2012,29(2):406-410.
[12] Park S,Koo JS,Kim MS,et al.Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers[J].Ann Oncol,2011,22(8):1755-1762.
[13] RicciardiG RR,Adamo B,Ieni A,et al.Androgen receptor (AR),E-cadherin,and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients[J].PLoS One,2015,10(6):10-18.
[14] Hilborn E,Gacic J,Fornander T,et al.Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer[J].Br J Cancer,2016,114(3):248-255.
[15] Pietri E,Conteduca V,Andreis D,et al.Androgen receptor signaling pathways as a target for breast cancer treatment[J].Endoc Relat Cancer,2016,23(10):R485-R498.
[16] Payandeh M,Shazad B,Madani S,et al.Androgen receptor expression and its correlation with other risk factors in triple negative breast cancers:a report from Western Iran[J].Asian Pac J Cancer Prev,2016,17(7):3321-3324.
[17] Liu YX,Wang KR,Xing H,et al.Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers[J].Oncol Lett,2016,12(2):1240-1256.
[18] Jiang HS,Kuang XY,Sun WL,et al.Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status[J].Oncotarget,2016,7(27):41285-41293.
[19] Bianchini G,Balko JM,Mayer I A,et al.Triple-negative breast cancer:challenges and opportunities of a heterogeneous disease[J].Nat Rev Clin Oncol,2016,13(11):674-690.
[20] Thakkar A,Wang B,Picon-Ruiz M,et al.Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer[J].Breast Cancer Res Treat,2016,157(1):77-90.
[21] Kim S,Moon BI,Lim W,et al.Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer[J].Hum Pathol,2016,55:190-195.
[22] Cinkaya A,Akin M,Sengul A.Evaluation of treatment outcomes of triple-negative breast cancer[J].J Cancer Res Ther,2016,12(1):150-154.
[23] 陈健,张旭,田茹,等.不同ER、PR状态乳腺癌中AR的表达及其意义[J].临床与实验病理学杂志,2010,26(1):52-55.
[24] 方茅,翁泽平,关弘,等.三阴性乳腺癌组织DJ-1和PTEN及AR表达与预后相关性分析[J].中华肿瘤防治杂志,2013,20(10):761-764.
[25] 陈健,张旭,田茹,等.雄激素受体在乳腺癌中的表达及其与雌、孕激素受体和HER2的关系[J].中华病理学杂志,2010,39(11):743-746.
[26] Pistelli M,Ballatore Z,Santinelli A,et al.Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer[J].Oncol Rep,2016,36(2):755-762.
[27] 迪力夏提·金斯汗,吐鲁洪·沙列尔,赵倩.EZH2抑制剂DZNeP对人乳腺癌细胞增殖、凋亡及相关信号通路的影响[J].中国老年学杂志,2016,36(16):3877-3879.
[28] 乔伟强,潘琳琳,寇长贵,等.局部晚期乳腺癌新辅助化疗病理完全缓解与预后相关性的Meta分析[J].中国老年学杂志,2016,36(16):3982-3985.

Meta-analysis on influence of androgen receptor in living conditions of patients with triple-negative breast cancer

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	QI Lu, BAI Wei, YU Weiying, LI Yuanyuan, HUA Wanqing, KOU Changgui. Randomized controlled trials for curative effect of saxagliptin combined with insulin in treatment of patients with type 2 diabetes mellitus: Meta-analysis [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1235-1242.
[2]	QUAN Xiaoyue, LIU Bailong, LIU Min, DONG Lihua. Treatment of lung squamous cell carcinoma with apatinib in patient who couldn't tolerate chemotherapy: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 624-627.
[3]	NIU Huikun, QU Yangming, LI Meiqi, LI Lu, LYU Xin, SONG Yuanyuan, GAO Chunshi, LI Bo. Meta-analysis on efficacy and adverse effects of neoadjuvant chemotherapy combined with capecitabine in treatment of breast cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(06): 1171-1176.
[4]	YAO Yanan, YAO Hua, YAN Duoduo, LYU Kejia, GONG Lijun, WANG Guohua. Meta-analysis on correlation between oral lichen planus and Candida albicans infection [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 967-974.
[5]	NIU Meng, DENG Dayong, LI Yunpengfei, LIU Shuo, DING Jun. Values of MRE in diagnosis of stages of hepatic fibrosis:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 787-793.
[6]	ZHANG Yang, WANG Junfeng, CAOHongyan, QIN Ling, XU Guoliang. Effectiveness and safety of Dengzhanhuasu and Dansheng Injection in treatment of patients with angina pectoris of coronary heart disease:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 317-321.
[7]	MA Ranyang, YU Hong, WANG Xin. Evaluation on clinical efficacy of hyperbaric oxygenation in treatment of sudden deafness:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 298-305.
[8]	XU Jin, CHEN Huaiji, XU Feng, WANG Qi, ZHANG Yuezhu, LIU Hongbo, ZHANG Tianrong, YE Lin. Association between phthalate ester exposure and population obesity:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 306-310.
[9]	SUN Di, WANG Qi, CHEN Haiji, XU Feng, ZHANG Yuezhu, ZHANG Tianrong, LIU Hongbo, YE Lin. Changes of serum thyroid hormone levels in DEHP exposure population: A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 66-72.
[10]	LI Xingxing, TAN Jingjin, JIANG Shan, WAHG Ke. Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1116-1125.
[11]	SU Yingying, LIU Yingyu, ZHANG Yangyu, MA Yue, YANG Guang, YOU Yueyue, FU Yingli, KOU Changgui. Network Meta-analysis of 9 kinds of Chinese herb injections combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1126-1131.
[12]	DU Biao, XIE Xingxing, ZHANG Jie, FAN Xiaodong, YE Yun. Systematic review of efficacy and safety of rosuvastatin in treatment of patients with primary hyperlipidemia in China [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 968-974.
[13]	TAO Ruying, LI Miao, ZHANG Hui. Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with risperidone in treatment of schizophrenia [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 757-762.
[14]	ZU Dongni, ZHAO Mingyi, DU Wei, ZHAO Weichao, JIA Shubing, YANG Jingyu, XIANG Rongwu. Meta-analysis on safety of recombinant human brain natriuretic peptide in treatment of acute decompensated heart failure [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 768-776.
[15]	DING Xianfei, ZHOU Xueliang, DOU Mengmeng, LI Lifeng, GUO Lina, WANG Feng, FAN Qingxia. Expression of mTOR and its relationship with prognosis of breast cancer: a Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 783-788.